How Much Vitamin K2 to Reverse Calcification?

No dose of vitamin K2 has been proven to reverse existing vascular calcification in humans. The strongest clinical trial to date, using 720 micrograms per day of MK-7 combined with vitamin D over two years, managed to slow calcification progression in people who already had severe coronary artery calcium scores, but it did not shrink those deposits. The gap between “slowing down” and “reversing” is wide, and understanding that distinction matters before you spend money on supplements or, worse, delay medical treatment.

Why Vascular Calcification Is So Hard to Undo

For decades, calcium buildup in arteries was dismissed as an inevitable part of aging, like rust on old pipes. That view has been replaced by something more complicated and, in some ways, more frustrating. Vascular calcification is now understood as an actively regulated, cell-driven process that resembles bone formation.¹ Smooth muscle cells in artery walls can transform into osteoblast-like cells, essentially bone-building cells in the wrong location, and begin depositing calcium-phosphate crystals into the vessel wall.² Once those mineral deposits are established, they behave like mature bone tissue, with their own structural integrity. Dissolving bone-like deposits in a living artery without damaging the vessel is a problem nobody has solved yet.

This is the core reason that “reversing” calcification with any supplement remains aspirational rather than demonstrated. The biological machinery that lays down the calcium is well understood. The machinery that would remove it, in a controlled and safe way, barely exists in human physiology. What the body does have is a set of natural inhibitors that can prevent new deposits from forming and slow the growth of existing ones. Vitamin K2 fits into that prevention-and-slowing category, not the reversal category.

How Vitamin K2 Fits Into the Picture

The connection between vitamin K2 and calcification runs through a protein called matrix Gla protein, or MGP. MGP is one of the body’s most potent natural inhibitors of calcification. It works locally in blood vessel walls, grabbing calcium ions and preventing them from crystallizing where they shouldn’t.³ But MGP only works if it has been “activated” through a chemical modification called carboxylation, and that step requires vitamin K as a cofactor.⁴ Without enough vitamin K, MGP sits around in its inactive form, unable to do its job. Blood levels of this inactive form, called dp-ucMGP, serve as a marker of vitamin K insufficiency and have been linked to cardiovascular risk.⁵

So the logic behind vitamin K2 supplementation is sound at the molecular level: more vitamin K2 in circulation means more MGP gets activated, which means stronger local inhibition of new calcium deposits. Supplementation studies consistently show that K2 lowers dp-ucMGP levels, confirming that the biochemical pathway responds as expected.⁶ The problem is that lowering a biomarker and actually changing calcification outcomes are two different things.

What the Clinical Trials Actually Show

Three randomized controlled trials stand out in this area, and their results tell a consistent story: vitamin K2 can nudge calcification progression in the right direction, but the effects are modest and sometimes statistically insignificant.

The largest and most relevant is the AVADEC trial, conducted in Denmark. It enrolled men with coronary artery disease (average age 71) and gave them 720 micrograms per day of MK-7 plus 25 micrograms of vitamin D, or a placebo, for two years. Both groups saw their coronary artery calcium scores increase over that period, because calcification tends to progress. But in the subgroup with the most severe calcification (scores above 400), the supplementation group progressed more slowly. The mean increase was roughly 288 versus 380 Agatston units, a statistically significant difference.⁷ Safety events were also fewer in the supplementation group. It is worth emphasizing that even in this best-case subgroup, calcium scores still went up. The supplement slowed the climb; it did not reverse it.

When the same trial looked at aortic valve calcification specifically, the results were less encouraging. The progression of aortic valve calcium scores was not significantly different between the treatment and placebo groups.⁸ Aortic valve area and peak jet velocity, both measures of how well the valve is functioning, also showed no meaningful change. This suggests that calcification in different anatomical locations may not respond equally to supplementation.

A third trial, the Trevasc-HDK study, looked at hemodialysis patients, a population with extremely high calcification rates. After 18 months of vitamin K2 supplementation, there was no significant difference in coronary artery or aortic valve calcium scores between the treatment and placebo groups.⁶ The composite outcome of major cardiac events and death was also no different. The supplements did lower dp-ucMGP levels, so the biochemistry worked as expected, but it did not translate into measurable changes in calcification or clinical outcomes. Kidney disease creates such a severe pro-calcification environment that the protective effect of activated MGP may simply be overwhelmed.

Doses Used in Research and What They Mean for You

If you are going to try vitamin K2 supplementation anyway, the dose that has the most clinical support behind it is 720 micrograms per day of MK-7, combined with vitamin D. That was the dose used in the AVADEC trial, the only trial to date showing a statistically significant slowing of coronary artery calcification in any subgroup.⁹ That is a substantially higher dose than what most over-the-counter supplements provide, which typically range from 90 to 200 micrograms.

Whether those lower doses do anything meaningful for calcification is unclear. They do appear to be enough to improve carboxylation of vitamin K-dependent proteins. Research on osteocalcin, another vitamin K-dependent protein involved in bone health, shows that nutritional doses of MK-7 between 45 and 90 micrograms per day are sufficient to increase osteocalcin carboxylation.¹⁰ But carboxylating osteocalcin in the bloodstream and generating enough activated MGP to meaningfully slow arterial calcification may require quite different amounts. No trial has tested whether, say, 200 micrograms of MK-7 per day slows calcification progression. The evidence sits at two points: nutritional doses activate circulating proteins, and 720 micrograms per day slowed coronary calcification in men with severe disease. The gap between those two data points is largely unfilled.

MK-7 Versus MK-4 and Why the Form Matters

Vitamin K2 is not a single molecule. It comes in several forms called menaquinones, abbreviated MK followed by a number that reflects the length of their side chain. The two you will encounter in supplements are MK-4 and MK-7. They differ in ways that matter for this topic.

MK-7, the long-chain form found naturally in fermented foods, has a much longer half-life in the blood. After a dose, MK-7 can be detected in plasma for up to 96 hours, compared with 8 to 24 hours for MK-4 and vitamin K1.¹¹ This extended presence gives MK-7 more time to reach tissues throughout the body, including artery walls. MK-4, by contrast, is cleared so quickly that even daily supplementation at nutritional doses does not reliably raise plasma levels.¹⁰ In Japan, MK-4 is prescribed at pharmacological doses of 45 milligrams per day for osteoporosis, which is roughly 50 to 100 times larger than typical MK-7 supplement doses. At those massive doses, MK-4 has effects on bone, but nobody has tested those doses for vascular calcification in controlled trials.

The structural differences between K1 and K2 also result in different tissue distribution and bioavailability.¹² Vitamin K1, found in leafy greens, is primarily taken up by the liver for clotting factor production and does not appear to reach extrahepatic tissues as efficiently as MK-7. For arterial health specifically, MK-7 is the form with the most relevant research behind it.

The Warfarin Problem

If you take warfarin or another vitamin K antagonist anticoagulant, vitamin K2 supplementation is a serious concern. Warfarin works by blocking the enzyme that recycles vitamin K, which is exactly the enzyme your body needs to activate MGP and clotting factors. Taking extra vitamin K2 directly counteracts the drug.

Research quantifies this risk clearly. In healthy volunteers stabilized on warfarin, daily MK-7 doses as low as 45 micrograms reduced their INR (the measure of how effectively the blood is being thinned) by about 20% after one week and 37% after two weeks.¹³ Doses of 10 to 20 micrograms per day did not significantly move the INR. That means even a modest supplement sitting on a store shelf at 100 or 200 micrograms could substantially destabilize anticoagulation therapy. If you are on warfarin and interested in vitamin K2 for calcification, that conversation belongs with your prescribing physician, not in a supplement aisle. Some researchers have explored the idea of using small, stable K2 doses to smooth out the erratic INR swings that plague warfarin therapy, but this remains investigational.

For people not on anticoagulants, the safety profile of MK-7 is reassuring. Toxicology studies in animals show an extremely wide safety margin. A 90-day study in rats found no adverse effects at the highest dose tested, and acute toxicity studies show no harm at doses far beyond anything a human would consume from supplements.¹⁴ No upper tolerable intake level has been established for vitamin K2 by major health agencies, partly because toxicity appears to be extremely difficult to achieve. That said, “nontoxic” and “effective for calcification” are very different claims.

Why Vitamin D Keeps Showing Up Alongside K2

You will notice that the strongest trial, AVADEC, did not test K2 alone. It used K2 combined with vitamin D. This was not an accident. Vitamin D promotes the production of vitamin K-dependent proteins, including MGP and osteocalcin. Without adequate vitamin D, the body may not produce enough of these proteins for vitamin K2 to activate.¹⁵ The two vitamins work in sequence: D drives production, K enables activation. Taking one without the other may limit the benefit.

There is an ironic twist here. High-dose vitamin D supplementation without adequate vitamin K may actually worsen calcification, because vitamin D increases calcium absorption from food. If that calcium reaches the bloodstream and the MGP inhibition system is not fully online due to low vitamin K status, you could theoretically accelerate the very problem you are trying to prevent. This concern comes from mechanistic reasoning more than direct trial evidence, but it is one reason many clinicians recommend that people taking vitamin D also pay attention to their vitamin K intake.

Genetic Variation in Vitamin K Metabolism

Not everyone processes vitamin K the same way, and this may help explain why some people develop calcification despite apparently adequate diets. A genetic variant in the VKORC1 gene, which encodes the enzyme responsible for recycling vitamin K in the body, has been linked to aortic calcification risk. Carriers of the T-allele at a specific site in this gene had a roughly 19% higher risk of calcification of the aortic wall compared to people with the CC genotype.¹⁶

This is the same gene that determines warfarin dose sensitivity. People who need lower warfarin doses to achieve the same blood-thinning effect tend to carry variants that make their vitamin K recycling enzyme less efficient. If that enzyme is naturally less active, it follows that these individuals might also have less efficient MGP activation, even at “normal” dietary vitamin K intakes. Whether these people would benefit more from supplementation has not been tested directly, but the genetics suggest that a one-size-fits-all dose recommendation may be overly simplistic.

Kidney Disease Changes the Equation

People with chronic kidney disease face particularly aggressive vascular calcification, and the vitamin K angle becomes both more appealing and more complicated in this population. CKD patients tend to have markedly elevated dp-ucMGP levels, indicating poor vitamin K status and large amounts of inactive MGP.⁵ On paper, these patients would seem to have the most to gain from supplementation. In practice, the Trevasc-HDK trial in hemodialysis patients found no benefit for calcification scores despite successfully lowering dp-ucMGP.⁶

The likely explanation is that CKD creates a pro-calcification environment so extreme, with disordered phosphorus metabolism, chronic inflammation, and disrupted hormone signaling, that even fully activated MGP cannot keep up. Researchers in this field generally believe vitamin K supplementation should be part of a broader treatment strategy for CKD patients, but acknowledge that further trials are needed to establish the right dose and combination.¹⁷ If you have kidney disease and are considering K2, work with your nephrologist rather than self-supplementing.

Natto and Dietary Sources of MK-7

For people who want to get MK-7 from food rather than pills, the dominant dietary source is natto, a traditional Japanese fermented soybean product. A single 50-gram serving of natto delivers roughly 380 micrograms of MK-7, which is more than most commercial supplements and about half the daily dose used in the AVADEC trial.¹⁸ A meta-analysis of Japanese studies found that habitual natto intake significantly raised serum MK-7 levels and improved carboxylation of osteocalcin, the vitamin K-dependent protein involved in bone health.

Other fermented foods contain smaller amounts of various menaquinones. Certain aged cheeses, particularly Gouda and Edam, provide MK-9 and other longer-chain forms, though at much lower concentrations than natto. Fermented sauerkraut and some fermented dairy products contribute modest amounts. Liver and egg yolks contain MK-4, though as discussed earlier, dietary MK-4 has a short half-life and limited systemic bioavailability at food-level doses. For someone seriously trying to maximize their vitamin K2 intake through diet, natto is in a category by itself. The challenge is that many people outside Japan find its strong flavor and slimy texture difficult to eat regularly.

Aortic Valve Calcification and the Limits of Current Evidence

Coronary artery calcification and aortic valve calcification often get lumped together in popular discussions of “calcification,” but they appear to respond differently to vitamin K2. The AVADEC trial showed a statistically significant benefit for coronary artery calcification in the high-severity subgroup but essentially no benefit for aortic valve calcification.⁸ The BASIK2 trial was designed specifically to test MK-7 against calcification in bicuspid aortic valves using advanced imaging, reflecting the hypothesis that MGP activation could slow valve disease progression.¹⁹

The valve environment differs from the arterial wall in ways that may matter. Aortic valve calcification involves different mechanical stresses, different cell types, and different hemodynamic forces. It is plausible that MGP activation provides less protection in valves than in arteries, or that the calcification process in valves has progressed past the point where MGP-mediated inhibition can make a measurable difference by the time patients enter a trial. For people with diagnosed aortic stenosis, there is currently no evidence supporting K2 supplementation as a treatment, and the condition often progresses to the point where surgical or transcatheter valve replacement becomes necessary regardless.

1
PubMed Central. Vascular calcification: pathobiology of a multifaceted disease
2
PubMed Central. Vascular Calcification: Mechanisms of Vascular Smooth Muscle Cell Calcification
3
PubMed Central. Vitamin K–Dependent Matrix Gla Protein as Multifaceted Protector of Vascular and Tissue Integrity
4
PubMed Central. Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis
5
PubMed. Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease
6
PubMed Central. Randomized Controlled Clinical Trial of the Effect of Treatment with Vitamin K2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK)
7
PubMed Central. Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT
8
PubMed Central. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
9
PubMed Central. Effects of vitamins K2 and D3 supplementation in patients with severe coronary artery calcification: a study protocol for a randomised controlled trial
10
PubMed Central. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
11
PubMed Central. Relationship between Structure and Biological Activity of Various Vitamin K Forms
12
PubMed Central. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease
13
Journal of Thrombosis and Haemostasis. Effect of low-dose supplements of menaquinone-7 (vitamin K2) on the stability of oral anticoagulant treatment: dose–response relationship in healthy volunteers
14
PubMed Central. Safety evaluation of vitamin K2 (menaquinone-7) via toxicological tests
15
PubMed Central. The Synergistic Interplay between Vitamins D and K for Bone and Cardiovascular Health: A Narrative Review
16
PubMed. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study
17
PubMed Central. Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health
18
PubMed Central. Habitual natto intake elevates serum MK-7 levels, enhances osteocalcin carboxylation, and supports bone density: a meta-analysis of Japanese evidence
19
PubMed Central. Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using (18)F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design